Halobetasol propionate 0.05% lotion (Ultravate)


FDA Approved Indications:
  • Topical treatment of plaque psoriasis in patients 18 years of age and older
Prior authorization criteria:
  • Patient has a diagnosis of plaque psoriasis, AND
  • Patient is 18 years of age or older, AND
  • Patient has tried and failed the halobetasol cream
  • Apply a thin layer to affected areas twice daily
  • Limit use to 50 g/week
  • Discontinue when control is achieved
  • If no improvement is seen within 2 weeks, reassess diagnosis
  • Treatment beyond 2 consecutive weeks is not recommended
  • Avoid use on face, scalp, groin or axillae
  • Limited to a maximum of 2 weeks